Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL921 in Healthy Participants and Participants With Alzheimer's Disease
NCT07758595Phase 1Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Aug 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNL921 in Alzheimer's disease (AD) (2 arms), sponsored by Denali Therapeutics Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 242 days. Started Aug 2026; status: recruiting.
02
Drugs
DNL921
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07758595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758595.